The Forbes Asia 100 to Watch list focuses on emerging companies across the Asia-Pacific region that are gaining a foothold in some of the world's most dynamic industries, such as space technology, biotechnology, and robotics. Great Bay Bio is committed to the vision of "Global Bioprocessing Made Simpler and More Efficient." Throughout its development, GBB has focused on addressing many pain points in drug development, such as long timelines, high costs, and low success rates. This commitment aligns perfectly with the criteria for the Forbes Aais 100 to Watch, which emphasizes industry impact, regional contributions, market alignment, promising business models, innovation, and sustained revenue growth.

In the future, Great Bay Bio will continue to commit to its vision by utilizing AI platforms to drive innovation in bioprocessing technologies. The goal is to enhance the speed and quality of global drug discovery and CMC development, ultimately benefiting human health and well-being.